Doptelet®
(avatrombopag) tablets

Scan for additional details, including criteria for use[1]

DOPTELET® is Covered* with PA† on Veterans Health Administration Formulary[1]

NOTE: For VHA-specific issues, providers should contact their local facility Chief of Pharmacy.

For additional details, including criteria for use, please visit:

- Immune Thrombocytopenia (ITP) Criteria for Use[2]
- Thrombocytopenia in Chronic Liver Disease Criteria for Use[3]

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with:

- Chronic liver disease who are scheduled to undergo a procedure.
- Chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Please see additional Important Safety Information on the following page and Full Prescribing Information for DOPTELET at www.doptelethcp.com.

Coverage and reimbursement information is provided for your information only and is subject to change. For specific information, please contact the patient's insurer. Third-party payment for prescription drugs is affected by numerous factors, and Sobi makes no representation or guarantee concerning reimbursement or coverage for DOPTELET or any other service or item.

Please see page 2 for references.

INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with:

- Chronic liver disease who are scheduled to undergo a procedure.
- Chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions

The most common adverse reactions (≥3%) in patients with chronic liver disease were pyrexia, abdominal pain, nausea, headache, fatigue, and peripheral edema.

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com.

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

Information is current as of April 2023.

* **Covered:** Covered benefit for the listed payer.

† **PA:** Prior Authorization.

References: 1. https://www.va.gov/formularyadvisor/drugs/4037595-AVATROMBOPAG-TAB. Accessed April 2023; **2.** https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Avatrombopag_DOPTELET_ITP_Mar_2022.pdf. Accessed April 2023; **3.** https://www.va.gov/formularyadvisor/DOC_PDF/CFU_Avatrombopag_DOPTELET_Chronic_Liver_ Disease_Mar_2022.pdf. Accessed April 2023.

sobi
rare strength